Chester County News and Community Website
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received approval from the U.S. Food and Drug Administration (FDA) to transition to a new solid form of buntanetap in future …
Annovis Bio Gains FDA Approval for New Form of Neurodegenerative Drug Read More
WASHINGTON, D.C. — On Tuesday, the Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. This approval marks a major milestone in the fight …
FDA Approves Kisunla for Alzheimer’s Treatment, Marking Significant Progress Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will host an investor webcast on July 2, 2024, at 4:30 PM ET to discuss recent progress and future plans for its …
Annovis Bio to Host Investor Webcast on Buntanetap Developments Read More
PHILADELPHIA, PA — The Global CEO Initiative on Alzheimer’s Disease (CEOi), led by UsAgainstAlzheimer’s, has announced the publication of its latest recommendations on blood-based biomarker (BBM) tests in the journal …
New Standards Aim to Improve Early Alzheimer’s Diagnosis Through Blood Tests Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More
LANGHORNE, PA — Amplity Health, a leading Contract Sales and Medical Outsourcing Partner, unveiled insights into the profound impact of Alzheimer’s disease (AD) on patients’ quality of life. The findings …
Amplity Health Study Sheds Light on Alzheimer’s Disease’s Toll on Quality of Life Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has made a breakthrough in an ongoing study of Alzheimer’s disease. Their novel Alzheimer’s drug, buntanetap, which specifically targets neurotoxic proteins, has …
Groundbreaking Alzheimer’s Study Reveals Potential for Progression-Slowing Therapy Read More MALVERN, PA — In a significant development for Alzheimer’s Disease (AD) research, Annovis Bio, Inc. (NYSE: ANVS) has unveiled new data from a study indicating that buntanetap, an innovative oral …
Annovis Bio’s Buntanetap Shows Promise in Early Alzheimer’s Disease Study Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a Pennsylvania-based clinical-stage drug platform company, has announced the completion of the last patient visit in the phase II/III study of its …
Annovis Bio Wraps Up Phase II/III Trial for Alzheimer’s Drug Buntanetap Read More